Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7-H3 CAR T Cells in Children and Young Adults With Recurrent or Progressive CNS Neoplasms
NCT07390539Phase 1Recruiting
- Start
- Sep 2026
- Primary completion
- Aug 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of B7-H3 UCAR-T in central nervous system tumor, medulloblastoma, ependymoma and 3 more (4 arms). Primary endpoints: Manufacturing Success Rate of Autologous B7-H3.CD28Z CAR T Cells at Day 0, Maximum Tolerated Dose at 28 days and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
B7-H3 UCAR-T
03
Conditions
central nervous system tumormedulloblastomaependymomaAtypical teratoid rhabdoid tumor (ATRT)embryonal tumor with multilayered rosettes (ETMR)
Beyond the preview
Go deeper on NCT07390539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07390539.